Massachusetts-based Biogen (Nasdaq: BIIB) has provided a preview of the data it will present at the Alzheimer’s Association International Conference, the pre-eminent Alzheimer's meeting that takes place in London next week.
Poster presentations will include a new post-hoc analysis of a Phase Ib trial into aducanumab, showing a change in cognitive and functional subscores.
These changes were derived from a previously-reported clinical dementia rating (CDR) score for the overall and early Alzheimer’s disease populations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze